Compare RETO & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RETO | POAI |
|---|---|---|
| Founded | 1999 | 2002 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 6.5M |
| IPO Year | 2017 | N/A |
| Metric | RETO | POAI |
|---|---|---|
| Price | $2.61 | $5.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 436.5K | 42.7K |
| Earning Date | 05-05-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,109,956.00 | $1,664,407.00 |
| Revenue This Year | N/A | $486.27 |
| Revenue Next Year | N/A | $65.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16864.81 | 320.71 |
| 52 Week Low | $1.77 | $3.88 |
| 52 Week High | $61.50 | $45.90 |
| Indicator | RETO | POAI |
|---|---|---|
| Relative Strength Index (RSI) | 47.59 | 47.30 |
| Support Level | $1.77 | $3.88 |
| Resistance Level | $3.54 | $6.25 |
| Average True Range (ATR) | 0.57 | 0.76 |
| MACD | -0.11 | 0.11 |
| Stochastic Oscillator | 24.57 | 79.01 |
ReTo Eco-Solutions Inc is a manufacturer and distributor of eco-friendly construction materials and fly ash, as well as equipment used to produce these eco-friendly construction materials. The company engaged in providing consultation, design, project implementation, and construction of urban ecological environments for capturing, controlling, and reusing rainwater. It operates through two segments, namely Machinery and Equipment sales, and Technology Consulting and other services. The company earns its revenue from the Machinery and Equipment sales segment. Geographically, it derives a majority of its revenue from China.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.